Closing two doors of viral entry: Intramolecular combination of a coreceptor- and fusion inhibitor of HIV-1

Virology Journal

Volumn 5, Issue , 2008, Pages

  Kopetzki, Erhard ^a   Jekle, Andreas ^b   Ji, Changhua ^b   Rao, Eileen ^b   Zhang, Jun ^b   Fischer, Stephan ^a   Cammack, Nick ^b   Sankuratri, Surya ^b   Heilek, Gabrielle ^b  

^a Pharmaceuticals Division   (Germany)

^b ROCHE BIOSCIENCE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BIFUNCTIONAL FUSION INHIBITOR; CHEMOKINE RECEPTOR CCR5; ENFUVIRTIDE; HYBRID PROTEIN; MONOCLONAL ANTIBODY; CHEMOKINE RECEPTOR CXCR4; HUMAN IMMUNODEFICIENCY VIRUS FUSION INHIBITOR;

ANTIVIRAL ACTIVITY; ARTICLE; CELL FUSION; CELL LINE; DRUG HALF LIFE; DRUG MECHANISM; DRUG PROTEIN BINDING; HUMAN; HUMAN CELL; HUMAN IMMUNODEFICIENCY VIRUS 1; IC 50; MOLECULE; PERIPHERAL BLOOD MONONUCLEAR CELL; VIRUS ENTRY; ANIMAL; DRUG ANTAGONISM; DRUG EFFECT; IMMUNOLOGY; MEMBRANE FUSION; METABOLISM; MOUSE; PHYSIOLOGY; VIRUS ATTACHMENT;

HUMAN IMMUNODEFICIENCY VIRUS 1;

ANIMALS; CELL LINE; HIV FUSION INHIBITORS; HIV-1; HUMANS; INHIBITORY CONCENTRATION 50; MEMBRANE FUSION; MICE; RECEPTORS, CCR5; RECEPTORS, CXCR4; RECOMBINANT FUSION PROTEINS; VIRUS ATTACHMENT; VIRUS INTERNALIZATION;

EID: 44349096289     PISSN: None     EISSN: 1743422X     Source Type: Journal    
DOI: 10.1186/1743-422X-5-56     Document Type: Article

References (26)

1. HIV coreceptors: from discovery and designation to new paradigms and promise. G Alkhatib EA Berger, European journal of medical research 2007 12 9 375 384 17933717
2. The role of receptors in the HIV-1 entry process. R Jones M Nelson, European journal of medical research 2007 12 9 391 396 17933719
3. Structure and function of the HIV envelope glycoprotein as entry mediator, vaccine immunogen, and target for inhibitors. P Prabakaran AS Dimitrov TR Fouts DS Dimitrov, Adv Pharmacol 2007 55 33 97 17586312
4. A new classification for HIV-1. EA Berger RW Doms EM Fenyo BT Korber DR Littman JP Moore QJ Sattentau H Schuitemaker J Sodroski RA Weiss, Nature 1998 391 6664 240 10.1038/34571 9440686
5. Change in coreceptor use coreceptor use correlates with disease progression in HIV-1 - infected individuals. RI Connor KE Sheridan D Ceradini S Choe NR Landau, The Journal of experimental medicine 1997 185 4 621 628 9034141 10.1084/jem.185.4.621
6. Adaptation to promiscuous usage of CC and CXC-chemokine coreceptors in vivo correlates with HIV-1 disease progression. L Xiao DL Rudolph SM Owen TJ Spira RB Lal, AIDS (London, England) 1998 12 13 F137 43 9764773
7. CCR5-reactive antibodies in seronegative partners of HIV-seropositive individuals down-modulate surface CCR5 in vivo and neutralize the infectivity of R5 strains of HIV-1 In vitro. L Lopalco C Barassi C Pastori R Longhi SE Burastero G Tambussi F Mazzotta A Lazzarin M Clerici AG Siccardi, J Immunol 2000 164 6 3426 3433 10706739
8. Long-lasting CCR5 internalization by antibodies in a subset of long-term nonprogressors: a possible protective effect against disease progression. C Pastori B Weiser C Barassi C Uberti-Foppa S Ghezzi R Longhi G Calori H Burger K Kemal G Poli A Lazzarin L Lopalco, Blood 2006 107 12 4825 4833 16522810 10.1182/blood-2005-06-2463
9. Access denied? The status of co-receptor inhibition to counter HIV entry. P Biswas G Tambussi A Lazzarin, Expert opinion on pharmacotherapy 2007 8 7 923 933 10.1517/14656566.8.7.923 17472538
10. Differential inhibition of human immunodeficiency virus type 1 fusion, gp120 binding, and CC-chemokine activity by monoclonal antibodies to CCR5. WC Olson GE Rabut KA Nagashima DN Tran DJ Anselma SP Monard JP Segal DA Thompson F Kajumo Y Guo JP Moore PJ Maddon T Dragic, Journal of virology 1999 73 5 4145 4155 10196311
11. Potent, broad-spectrum inhibition of human immunodeficiency virus type 1 by the CCR5 monoclonal antibody PRO 140. A Trkola TJ Ketas KA Nagashima L Zhao T Cilliers L Morris JP Moore PJ Maddon WC Olson, Journal of virology 2001 75 2 579 588 11134270 10.1128/JVI.75.2.579-588.2001
12. Characterization of a Panel of Novel Human Monoclonal Antibodies that Specifically Antagonize CCR5 and Block HIV-1 Entry. C Roschke VS, Branco, L, Kanakaraj, P, Kaufman, T, Yao, X, Nardelli, B, Shi, Y, Cai, W,Ullrich, S,Bell, A,Teng, B, LaFleur, DW, Chowdhury, P,Kaithamana, S,Sosnovtseva, S,Albert, V, Moore, PA, Interscience Conference on Amtimicrobial Agents and Chemotherapy Washington, DC 2004
13. Safety, Pharmacokinetics, and Antiviral Activity of HGS004, a Novel Fully Human IgG4 Monoclonal Antibody against CCR5, in HIV-1-Infected Patients. J Lalezari GK Yadavalli M Para G Richmond E Dejesus SJ Brown W Cai C Chen J Zhong LA Novello MM Lederman GM Subramanian, J Infect Dis 2008 18266604
14. Novel CCR5 monoclonal antibodies with potent and broad-spectrum anti-HIV activities. C Ji M Brandt M Dioszegi A Jekle S Schwoerer S Challand J Zhang Y Chen L Zautke G Achhammer M Baehner S Kroetz G Heilek-Snyder R Schumacher N Cammack S Sankuratri, Antiviral research 2007 74 2 125 137 10.1016/j.antiviral. 2006.11.003 17166600
15. Mechanisms of Synergy Between HIV-1 Attachment, Coreceptor and Fusion Inhibitors. K Nagashima Rosenfield, S, Thompson, D, Maddon, P, Dragic, T, Olson, W, 8th Conference on Retroviruses and Opportunistic Infections Chicago, IL 2001
16. CCR5 small-molecule antagonists and monoclonal antibodies exert potent synergistic antiviral effects by cobinding to the receptor. C Ji J Zhang M Dioszegi S Chiu E Rao A Derosier N Cammack M Brandt S Sankuratri, Molecular pharmacology 2007 72 1 18 28 10.1124/mol.107.035055 17392523
17. Potent suppression of HIV-1 replication in humans by T-20, a peptide inhibitor of gp41-mediated virus entry. JM Kilby S Hopkins TM Venetta B DiMassimo GA Cloud JY Lee L Alldredge E Hunter D Lambert D Bolognesi T Matthews MR Johnson MA Nowak GM Shaw MS Saag, Nature medicine 1998 4 11 1302 1307 10.1038/3293 9809555
18. Design of helical, oligomeric HIV-1 fusion inhibitor peptides with potent activity against enfuvirtide-resistant virus. JJ Dwyer KL Wilson DK Davison SA Freel JE Seedorff SA Wring NA Tvermoes TJ Matthews ML Greenberg MK Delmedico, Proceedings of the National Academy of Sciences of the United States of America 2007 104 31 12772 12777 17640899 10.1073/pnas.0701478104
19. HIV-1 clones resistant to a small molecule CCR5 inhibitor use the inhibitor-bound form of CCR5 for entry. P Pugach AJ Marozsan TJ Ketas EL Landes JP Moore SE Kuhmann, Virology 2007 361 1 212 228 17166540 10.1016/j.virol.2006. 11.004
20. Reduced maximal inhibition in phenotypic susceptibility assays indicates that viral strains resistant to the CCR5 antagonist maraviroc utilize inhibitor-bound receptor for entry. M Westby C Smith-Burchnell J Mori M Lewis M Mosley M Stockdale P Dorr G Ciaramella M Perros, Journal of virology 2007 81 5 2359 2371 17182681 10.1128/JVI.02006-06
21. An anti-CCR5 monoclonal antibody and small molecule CCR5 antagonists synergize by inhibiting different stages of human immunodeficiency virus type 1 entry. D Safarian X Carnec F Tsamis F Kajumo T Dragic, Virology 2006 352 2 477 484 10.1016/j.virol.2006.05.016 16777164
22. Evidence that the transition of HIV-1 gp41 into a six-helix bundle, not the bundle configuration, induces membrane fusion. GB Melikyan RM Markosyan H Hemmati MK Delmedico DM Lambert FS Cohen, The Journal of cell biology 2000 151 2 413 423 11038187 10.1083/jcb.151.2.413
23. The HIV coreceptors CXCR4 and CCR5 are differentially expressed and regulated on human T lymphocytes. CC Bleul L Wu JA Hoxie TA Springer CR Mackay, Proceedings of the National Academy of Sciences of the United States of America 1997 94 5 1925 1930 9050881 10.1073/pnas.94.5.1925
24. R5 human immunodeficiency virus type 1 (HIV-1) replicates more efficiently in primary CD4+ T-cell cultures than X4 HIV-1. B Schweighardt AM Roy DA Meiklejohn EJ Grace 2nd WJ Moretto JJ Heymann DF Nixon, Journal of virology 2004 78 17 9164 9173 15308712 10.1128/JVI.78.17.9164-9173.2004
25. Coreceptor phenotype of natural human immunodeficiency virus with nef deleted evolves in vivo, leading to increased virulence. A Jekle B Schramm P Jayakumar V Trautner D Schols E De Clercq J Mills SM Crowe MA Goldsmith, Journal of virology 2002 76 14 6966 6973 12072497 10.1128/JVI.76.14.6966-6973.2002
26. The CCR5 mAB Pro 140 and Small-Molecule CCR5 Antagonists Possess Complementary HIV-1 Resistance Profiles. WC Olson Ketas, TJ, Franti, M, Kuhmann, SE, Moore, JP, Maddon, PJ, 46th Interscience conference on microbial agants and chemotherapy San Francisco, CA 2006